In Brief: SmithKline Beecham's Coreg
Executive Summary
SmithKline Beecham's Coreg: Cardiovascular & Renal Drugs Advisory Committee is scheduled to review carvedilol for congestive heart failure on May 2. On May 3, committee will review Boehringer Mannheim's reteplase (modified recombinant tissue plasminogen activator) for use in acute myocardial infarction. The committee also is scheduled to discuss digitalis for atrial ventricular tachycardia and CHF. Location has not been announced...